FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2486013003> ?p ?o ?g. }

• W2486013003 endingPage "02" @default.
• W2486013003 startingPage "P6" @default.
• W2486013003 abstract "Abstract Estrogen and the estrogen receptor (ER) are known to be prominent drivers of breast tumourigenesis and breast cancer progression. Hormonal agents that target the ER such as selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) are routinely used for the management for ER+ breast cancer. Fulvestrant is currently the only SERD approved for the treatment of ER-positive metastatic breast cancer, however, despite its clinical efficacy, the utility of fulvestrant has been limited by the amount of drug that can be administered in a single injection, the reduced bioavailability and the development of resistance in some patients. To overcome some of the challenges associated with current endocrine therapies there is a need for more durable and more effective ER-targeted therapies. RAD1901 is a novel, non-steroidal, orally bioavailable SERD. Preclinical studies demonstrated a favorable tissue selectivity profile, dose dependent ER degradation and potent inhibition of in vitro breast cancer cell proliferation. Significant tumor regression was consistently observed with RAD1901 treatment, compared to Tamoxifen or Fulvestrant in MCF7 and patient derived xenograft models, including those harboring ESR1 mutations. Here we describe a Phase 1 clinical study that was conducted in 52 healthy postmenopausal female volunteers. Cohorts of 10 subjects (2 placebo, 8 RAD1901 treated) were dosed with 200 mg, 500 mg, 750 mg or 1000 mg for 7 days. Additional subjects were enrolled to an 18F-estradiol positron emission tomography (FES-PET) cohort to evaluate the 200 mg (n=7 subjects) and 500 mg (n=6 subjects) dose levels. All dose levels were generally well tolerated with a total of 43/52 subjects completing the study. Pharmacokinetic analysis demonstrated good plasma exposure with dose proportional increases. FES-PET was performed at baseline and after 7 days of treatment with RAD1901, to assess estrogen receptor engagement. Standardized uptake values (SUV) pre- and post-treatment demonstrated a complete attenuation of FES-PET signal in ER-rich tissues such as the uterus at the 500 mg/day dose level, whereas almost 80% reduction in the signal was observed at the 200 mg/day dose level. Based on these preclinical and clinical results, RAD1901 is currently being investigated in a Phase 1 study for the treatment of hormone driven and hormone resistant metastatic breast cancers. Citation Format: Hattersley G, David F, Harris A, Clarkin M, Banks K, Glaudemans AWJM, Doorduin J, Koole M, de Vries EFJ, Williams G. A phase 1 dose escalation study of RAD1901, an oral selective estrogen receptor degrader, in healthy postmenopausal women. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-13-02." @default.
• W2486013003 created "2016-08-23" @default.
• W2486013003 creator A5002919999 @default.
• W2486013003 creator A5008844836 @default.
• W2486013003 creator A5017336039 @default.
• W2486013003 creator A5037547091 @default.
• W2486013003 creator A5042652051 @default.
• W2486013003 creator A5042999308 @default.
• W2486013003 creator A5048025570 @default.
• W2486013003 creator A5059831875 @default.
• W2486013003 creator A5066111936 @default.
• W2486013003 creator A5085198239 @default.
• W2486013003 date "2016-02-15" @default.
• W2486013003 modified "2023-09-26" @default.
• W2486013003 title "Abstract P6-13-02: A phase 1 dose escalation study of RAD1901, an oral selective estrogen receptor degrader, in healthy postmenopausal women" @default.
• W2486013003 doi "https://doi.org/10.1158/1538-7445.sabcs15-p6-13-02" @default.
• W2486013003 hasPublicationYear "2016" @default.
• W2486013003 type Work @default.
• W2486013003 sameAs 2486013003 @default.
• W2486013003 citedByCount "2" @default.
• W2486013003 countsByYear W24860130032019 @default.
• W2486013003 countsByYear W24860130032021 @default.
• W2486013003 crossrefType "journal-article" @default.
• W2486013003 hasAuthorship W2486013003A5002919999 @default.
• W2486013003 hasAuthorship W2486013003A5008844836 @default.
• W2486013003 hasAuthorship W2486013003A5017336039 @default.
• W2486013003 hasAuthorship W2486013003A5037547091 @default.
• W2486013003 hasAuthorship W2486013003A5042652051 @default.
• W2486013003 hasAuthorship W2486013003A5042999308 @default.
• W2486013003 hasAuthorship W2486013003A5048025570 @default.
• W2486013003 hasAuthorship W2486013003A5059831875 @default.
• W2486013003 hasAuthorship W2486013003A5066111936 @default.
• W2486013003 hasAuthorship W2486013003A5085198239 @default.
• W2486013003 hasConcept C121608353 @default.
• W2486013003 hasConcept C126322002 @default.
• W2486013003 hasConcept C143998085 @default.
• W2486013003 hasConcept C2777164284 @default.
• W2486013003 hasConcept C2777176818 @default.
• W2486013003 hasConcept C2777944059 @default.
• W2486013003 hasConcept C2780482068 @default.
• W2486013003 hasConcept C502942594 @default.
• W2486013003 hasConcept C530470458 @default.
• W2486013003 hasConcept C71924100 @default.
• W2486013003 hasConcept C84606932 @default.
• W2486013003 hasConcept C98274493 @default.
• W2486013003 hasConceptScore W2486013003C121608353 @default.
• W2486013003 hasConceptScore W2486013003C126322002 @default.
• W2486013003 hasConceptScore W2486013003C143998085 @default.
• W2486013003 hasConceptScore W2486013003C2777164284 @default.
• W2486013003 hasConceptScore W2486013003C2777176818 @default.
• W2486013003 hasConceptScore W2486013003C2777944059 @default.
• W2486013003 hasConceptScore W2486013003C2780482068 @default.
• W2486013003 hasConceptScore W2486013003C502942594 @default.
• W2486013003 hasConceptScore W2486013003C530470458 @default.
• W2486013003 hasConceptScore W2486013003C71924100 @default.
• W2486013003 hasConceptScore W2486013003C84606932 @default.
• W2486013003 hasConceptScore W2486013003C98274493 @default.
• W2486013003 hasIssue "4_Supplement" @default.
• W2486013003 hasLocation W24860130031 @default.
• W2486013003 hasOpenAccess W2486013003 @default.
• W2486013003 hasPrimaryLocation W24860130031 @default.
• W2486013003 hasRelatedWork W1488063118 @default.
• W2486013003 hasRelatedWork W159153186 @default.
• W2486013003 hasRelatedWork W1926498945 @default.
• W2486013003 hasRelatedWork W1986507544 @default.
• W2486013003 hasRelatedWork W2036698947 @default.
• W2486013003 hasRelatedWork W2051534472 @default.
• W2486013003 hasRelatedWork W2073293796 @default.
• W2486013003 hasRelatedWork W2088975813 @default.
• W2486013003 hasRelatedWork W2322892359 @default.
• W2486013003 hasRelatedWork W2953061480 @default.
• W2486013003 hasVolume "76" @default.
• W2486013003 isParatext "false" @default.
• W2486013003 isRetracted "false" @default.
• W2486013003 magId "2486013003" @default.
• W2486013003 workType "article" @default.